Personal/public health

Personal/public health, Public health

Opioid misuse is a public health crisis that has resulted in debilitation, deaths, and significant social and economic impact. The epidemic has been fueled by widespread abuse of prescription opioids and a dramatic increase in the availability of illicit opioids such as heroin. In this article, we examine some steps to overcoming this issue and improving the way we treat pain.
In a recent article, we discussed how the most prescribed drugs are usually indicated for common noncommunicable diseases. These include chronic conditions like diabetes, heart disease, GERD and mental health issues. Regarding treatment innovation, these prevalent diseases are often underserved when compared to less common, but more profitable, orphan diseases. In this article, we look at some of the underlying factors causing these noncommunicable diseases and what could be done to prevent them.
We recently sat down with Sjaak Vink, the visionary entrepreneur behind TheSocialMedwork. This enterprise gives patients all over the world access to medication that has not yet been approved in their home countries. We spoke with Vink about his personal motivations for founding TheSocialMedwork and his dream for universal basic healthcare.
With COVID-19 cases soaring into the millions, and a vaccine still a long way off, patients are desperate for a treatment. In response, numerous clinical trials have been initiated around the world. The majority of these trials are examining existing drugs to see if they can be repurposed to treat COVID-19. We spoke with Prof. Bart Lambrecht, pulmonologist at Ghent University Hospital (UZ Gent), about some of the clinical trials taking place here in Belgium.
Ghent, Belgium, April 2, 2020 - Biogazelle NV, a CRO specialized in RNA analytics, has announced the initiation of large-scale testing of patient samples for SARS-CoV-2. Biogazelle is providing one of the multiple testing sites in a government-led consortium of pharma, biotech, IT and academia, alongside Janssen Pharmaceutica (J&J), GSK, UCB, UgenTec, MIPS and ThermoFisher.
Over the past few months, every news headline has focused on COVID-19. The industry is accelerating its own in-house research to match the pace of the pandemic. The business development market is wide open, as large and mid-sized pharma companies are interested in partnering with early stage initiatives to advance investigational COVID-19 programs (in addition to pursuing their own in-house activities).
Mechelen, Belgium, 24 March 2020 - The coronavirus has brought the whole world to a standstill. The Belgian company ElmediX wants to contain the virus with intensive heat treatments for corona patients. Controlled heating to 41.5 °C for three hours can inactivate the virus and activate the patient's immune system. ElmediX has launched a call to researchers and doctors and makes the technology available in the fight against the coronavirus.
Pharmaceutical company Janssen Pharmaceutica and gin distillery Filliers Distillery are making disinfectant hand gel from Sunday. They will distribute it among the Belgian hospitals.
At the University of Antwerp, twelve product developers are working day and night to develop oral masks. "Together with industrial partners, we try to set up an emergency production for protective equipment for health workers during this corona crisis".
Developing a vaccine takes a long time and occurs in different phases. A virus spreads quickly and unpredictably. Therefore, the outcome is a gamble for anyone in the race for the corona vaccine.
The Bill & Melinda Gates Foundation is to provide samples of 15,000 therapeutic molecules to the Gasthuisberg hospital at the University of Leuven, to aid research into therapies to combat the coronavirus COVID-19, De Standaard reports.
Earlier this year, the lab of Xavier Saelens (VIB-UGent) announced the discovery of a unique antibody that is capable of binding the virus that causes COVID-19 (SARS-CoV-2). The antibody was developed in collaboration with two research groups in the US. The team has now established that the antibody can neutralize a lab variant of the virus, an important step forward in the development of a potential antiviral drug against the new coronavirus. This progress was made possible thanks to the intensive efforts of various teams in the VIB-UGent Center for Medical Biotechnology.
Hetty Helsmoortel is a science communicator who has dedicated herself to bringing research breakthroughs to a broader audience. In her recent book “De Geknipte Genen”, she tackles CRISPR: a revolutionary gene editing technology whose applications raise tricky ethical questions. We sat down with Dr. Helsmoortel to discuss her views on CRISPR’s potential and why she feels it is so important for the public to be well informed on this technical topic.
Novosanis have been able to achieve great success with their clever yet simple urine sampling solution Colli-Pee®, largely thanks to their multidisciplinary approach to product development. We spoke with Novosanis CEO Vanessa Vankerckhoven about the company’s interesting origin story.